Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Gain Therapeutics (Nasdaq: GANX) management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, including a fireside chat at 1:20 p.m. ET.
A replay will be made available via the company website and investors can request one-on-one meetings through Oppenheimer or by contacting ir@gaintherapeutics.com.
Positive
- None.
Negative
- None.
News Market Reaction – GANX
On the day this news was published, GANX declined NaN%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GANX showed a modest 1.1% gain while close peers were mixed: APLT -0.58%, CAMP -1.23%, INKT -0.9%, ALXO +2.2%, MNOV -7.1%, suggesting stock-specific trading rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 07 | Conference participation | Neutral | -5.5% | Participation in multiple events during J.P. Morgan Healthcare week. |
| Jan 06 | Clinical data update | Positive | -14.1% | Phase 1b biomarker and clinical data for GT-02287 after 90 days. |
| Dec 18 | KOL event announcement | Positive | -44.4% | Announcement of virtual KOL event on GT-02287 for Parkinson’s. |
| Dec 18 | Phase 1b results | Positive | -44.4% | Positive exploratory endpoint data from Phase 1b GT-02287 study. |
| Nov 20 | Preclinical data | Positive | +3.6% | Preclinical GT-02287 data showing mitochondrial and neuronal benefits. |
Recent history shows frequent negative price reactions following generally positive or neutral updates, including clinical progress and corporate event participation.
Over the last few months, Gain Therapeutics has focused on communicating progress around lead candidate GT-02287 and engaging investors through scientific and investor events. Positive Phase 1b and preclinical data, as well as KOL and conference presentations (e.g., J.P. Morgan week in Jan 2026), often coincided with sharp declines of up to -44.44%, with only the Nov 20 preclinical data showing a mildly positive market response. Today’s conference-participation news fits this pattern of non-fundamental, visibility-oriented updates.
Regulatory & Risk Context
An effective mixed shelf on Form S-3/A filed Nov 7, 2025 registers up to $100,000,000 of securities for potential future issuance, including equity, debt, and warrants, primarily for working capital and general corporate purposes. As of the latest data provided, there is no recorded usage of this shelf.
Market Pulse Summary
This announcement centers on Gain Therapeutics’ participation in the Oppenheimer healthcare conference, adding to a series of investor and scientific events following recent GT-02287 data. While not a fundamental update, it underscores efforts to increase visibility and engage with institutions. In context of prior sharp moves around positive news, investors may watch for future clinical milestones, financing actions under the $100,000,000 shelf, and broader sector trends when assessing risk.
AI-generated analysis. Not financial advice.
BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s management team will participate in a fireside chat and one-on-one meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held Wednesday, February 25th through Thursday, February 26th.
Fireside Chat Details
Date: Wednesday, February 25, 2026
Time: 1:20 p.m. ET
To access a replay of the fireside chat visit here or the “Investors & Media/News & Events” section of the Company’s website at https://gaintherapeutics.com.
Registered attendees can request one-on-one meetings with Gain management via their Oppenheimer banking representative.
If you are unable to attend the conference and would like to schedule a meeting with Gain management, please contact ir@gaintherapeutics.com.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. Forward-looking statements include all statements other than statements of historical fact contained in this release, including statements regarding the development of our current or future product candidates including GT-02287; expectations regarding the completion and timing of results from a Phase 1b clinical study for GT-02287, including any extension studies; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287, including any extension studies; the timing of any submissions to the FDA or other regulatory bodies and agencies; our anticipated cash runway; industry environment and potential licensing opportunities; and the potential therapeutic and clinical benefits of our product candidates. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on March 27, 2025, and our other filings with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.
Investors:
Gain Therapeutics, Inc.
Apaar Jammu
Director, Investor Relations and Public Relations
ajammu@gaintherapeutics.com
LifeSci Advisors LLC
Chuck Padala
Managing Director
chuck@lifesciadvisors.com
Media:
Russo Partners LLC
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
FAQ
When will Gain Therapeutics (GANX) present at the Oppenheimer conference in February 2026?
How can investors watch the Gain Therapeutics (GANX) fireside chat replay after February 25, 2026?
How can registered attendees schedule one-on-one meetings with Gain Therapeutics (GANX) at the Oppenheimer conference?
What should investors do if they cannot attend the Oppenheimer conference but want a meeting with Gain Therapeutics (GANX)?
What topics will Gain Therapeutics (GANX) management cover at the Oppenheimer 36th Annual Healthcare Life Sciences Conference?
